

Resolutions at the annual general meeting 2017 in Camurus

Lund, Sweden – 3 May 2017 — Camurus AB's (CAMX) annual general meeting 2017 was held today, Wednesday 3 May, at Elite Hotel Ideon in Lund. At the meeting, the following principal resolutions were passed.

Election of Board members and auditor

Per-Anders Abrahamsson, Marianne Dicander Alexandersson, Martin Jonsson, Svein Mathisen, Fredrik Tiberg, Kerstin Valinder Strinnholm and Per Olof Wallström were re-elected as Board members. Per Olof Wallström was re-elected as chairman of the Board. Per Sandberg had declined re-election. The accounting company PricewaterhouseCoopers AB was re-elected as auditor with Ola Bjärehäll as auditor in charge.

Fees

It was resolved that the fees to the Board shall amount to SEK 500,000 to the chairman of the Board and SEK 175,000 to each other Board members elected by the general meeting and not employed by the company. For work in the committees, it was further resolved that the chairman of the Audit Committee shall receive SEK 100,000 and that the other members of the Audit Committee shall receive SEK 50,000 each, and that the chairman of the Remuneration Committee shall receive SEK 50,000 and that the other members of the Remuneration Committee shall receive SEK 25,000 each.

Appropriation of the company's earnings

The meeting resolved in accordance with the Board's proposed appropriation of the company's earnings, entailing that the available funds of the parent company, SEK 534,823,232 in total, should be carried forward and that no dividend should be paid for the financial year 2016.

Guidelines for remuneration to senior executives

In accordance with the proposal by the Board, the meeting resolved on guidelines for remuneration to senior executives mainly corresponding to the guidelines adopted by the annual general meeting 2016. The guidelines principally entail that salaries and other terms of remuneration to the management shall be in accordance with market practice and that variable cash remuneration shall amount to a maximum of 50 percent of the fixed salary for the CEO and other senior executives. Fixed salary during notice period and severance pay shall in total not exceed an amount equivalent to the fixed salary for 18 months for the CEO and 12 months for other senior executives.

Authorisation for the Board of Directors to resolve on new share issues

In accordance with the proposal from the Board, the meeting resolved to authorise the Board of Directors to resolve on new share issues. The authorisation may be exercised on one or several occasions up to the annual general meeting 2018, and a maximum of 3,728,148 shares, corresponding to 10 percent of the company's share capital, may be issued. An issue may be made with or without deviation from the shareholders' preferential right and against cash payment, by set-off or by contribution in kind.

Resolution on incentive program

In accordance with the proposal from the Board, the meeting resolved on an incentive program for the company's employees. The program entails that a maximum of 750,000 subscription warrants shall be issued to Camurus' wholly owned subsidiary Camurus Development AB, for further transfer to the company's employees. Transfer shall take place before of the company's annual general meeting 2018 at market value at the time of transfer, and allotment shall be made in accordance with the principles set out in the Board's proposal. Subscription of shares by exercise of subscription warrants shall take place during the period from 15 May 2020 to 15 December 2020. The subscription price per share shall correspond to 140% of the volume weighted mean value according to Nasdaq Stockholm's official price list for share in the company during the period from 10 May 2017 up to and including 16 May 2017. As part of the incentive program, participants may receive a three-piece stay-on bonus in the form of gross salary additions from the company, in total equivalent to the amount paid by the participant for its subscription warrants, provided that the participant at the time for each payment remains in its employment. The maximum dilution effect of the program is approximately 2.0 percent.

For more information:

Fredrik Tiberg, CEO and Head of Research

Tel. +46 (0)46 286 46 92

fredrik.tiberg@camurus.com

About Camurus

Camurus is committed to developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic conditions, including opioid dependence, pain, cancer and endocrine disorders. New drug products are based on our proprietary FluidCrystal® drug delivery technologies with the purpose to deliver improved quality of life, treatment outcomes and resource utilization. The company's share is listed on Nasdaq Stockholm under the ticker "CAMX". For more information, visit www.camurus.com.

The information was submitted for publication at 19.00 PM CET on 3 May 2017.

Press release.pdf